Filtered By:
Vaccination: Cervical Cancer Vaccine

This page shows you your search results in order of relevance. This is page number 17.

Order by Relevance | Date

Total 852 results found since Jan 2013.

Nine-Valent HPV Vaccine Protects Against Additional Oncogenic Strains (FREE)
By Anna Wald, MD, MPH The new, nine-valent vaccine against human papillomavirus (HPV) shows nearly 100% efficacy against disease caused by five additional HPV strains, a New England Journal of Medicine study finds.Industry-funded researchers randomized over 14,000 young women to receive the quadrivalent vaccine (which protects against HPV 6, 11, 16, and 18) or the …
Source: Physician's First Watch current issue - February 19, 2015 Category: Primary Care Source Type: news

New HPV approved after international phase 2/3 trial involving Moffitt Cancer Center
(H. Lee Moffitt Cancer Center & Research Institute) A pivotal international phase 2/3 clinical trial involving Moffitt Cancer Center faculty demonstrated that vaccination with Gardasil 9 protects against nine HPV types, seven of which cause most cases of cervical, vulvar, and vaginal disease. The trial data indicate that if populations are vaccinated with Gardasil 9 approximately 90 percent of all cervical cancers worldwide can be prevented.
Source: EurekAlert! - Medicine and Health - February 20, 2015 Category: Global & Universal Source Type: news

Effect of Provider Prompts on Adolescent Immunization Rates: A Randomized Trial
Conclusions and Relevance: In both a local and national setting, provider prompts failed to improve adolescent immunization rates. More rigorous practice-based changes are needed.
Source: Academic Pediatrics - March 3, 2015 Category: Pediatrics Source Type: research

A prime/boost strategy using DNA/fowlpox recombinants expressing the genetically attenuated E6 protein as a putative vaccine against HPV-16-associated cancers
Conclusions: These data establish a preliminary indication for the prevention and treatment of HPV-related tumors by the use of DNA and avipox constructs as safe and effective immunogens following a prime/boost strategy. The combined use of recombinants expressing both E6 and E7 proteins might improve the antitumor efficacy, and should represent an important approach to control HPV-associated cancers.
Source: Journal of Translational Medicine - March 5, 2015 Category: Research Authors: Massimiliano BissaElena IllianoSole PacchioniFrancesca PaoliniCarlo ZanottoCarlo De Giuli MorghenSilvia MassaRosella FranconiAntonia RadaelliAldo Venuti Source Type: research

Oryx completes VicOryx Phase I/IIa trial for HPV-associated cancers
Translational medicine firm Oryx has completed a Phase I/IIa trial of the therapeutic vaccine VicOryx to treat p16INK4a-overexpressing Human Papilloma Virus (HPV) positive cancer patients.
Source: Drug Development Technology - March 9, 2015 Category: Pharmaceuticals Source Type: news

Exploring the Barriers to Patients Receiving the Human Papillomavirus (HPV) Vaccination (Krista Marie Collman MD)
This study explored some reasons that may help explain why HPV vaccination rates are low among Family Health Center patients.
Source: Family Medicine Digital Resources Library (FMDRL) Recently Uploaded - April 16, 2015 Category: Primary Care Source Type: news

HPV vaccine should not be delayed
(Queen's University) New research out of Queen's University shows early benefits from the human papillomavirus vaccine in young girls.
Source: EurekAlert! - Medicine and Health - April 27, 2015 Category: Global & Universal Source Type: news

Human papillomavirus DNA in men who have sex with men: type-specific prevalence, risk factors and implications for vaccination strategies
nds & P Sonnenberg
Source: British Journal of Cancer - April 28, 2015 Category: Cancer & Oncology Authors: E M KingR GilsonS BeddowsK SoldanK PanwarC YoungP PrahM JitW J EdmundsP Sonnenberg Tags: Human papillomavirus (HPV) MSM sexual health clinic genitourinary medicine clinic immunisation cross-sectional survey Source Type: research

Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
CONCLUSIONS: When comparing the costs and benefits of HPV vaccine introduction in Honduras, it is clear that this intervention would be highly cost-effective and that the intervention would greatly reduce cervical cancer disease. For these reasons, it is in the country's best interest to explore financing opportunities that could support the vaccine's introduction. PMID: 25919157 [PubMed - in process]
Source: Vaccine - May 2, 2015 Category: Allergy & Immunology Authors: Aguilar IB, Mendoza LO, García O, Díaz I, Figueroa J, Duarte RM, Perdomo G, Garcia AG, Janusz CB Tags: Vaccine Source Type: research

Impact of an Electronic Health Record (EHR) Reminder on Human Papillomavirus (HPV) Vaccine Initiation and Timely Completion
Conclusion: More patients aged 9 to 26 years initiated and achieved timely completion of the HPV vaccine series in clinics using an electronic health record system with prompts compared with clinics without prompts.
Source: Journal of the American Board of Family Medicine - May 8, 2015 Category: Primary Care Authors: Ruffin, M. T., Plegue, M. A., Rockwell, P. G., Young, A. P., Patel, D. A., Yeazel, M. W. Tags: Original Research Source Type: research

Sexual Orientation Identity and Human Papillomavirus Vaccination.
Authors: PMID: 25961832 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - May 12, 2015 Category: Internal Medicine Tags: Ann Intern Med Source Type: research

Sexual Orientation Identity Disparities in Awareness and Initiation of the Human Papillomavirus Vaccine Among U.S. Women and Girls: A National Survey.
Conclusion: Adolescent and young adult lesbians may be less likely to initiate HPV vaccination than their heterosexual counterparts. Programs should facilitate access to HPV vaccination services among young lesbians. Primary Funding Source: National Cancer Institute. PMID: 25961737 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - May 12, 2015 Category: Internal Medicine Authors: Agénor M, Peitzmeier S, Gordon AR, Haneuse S, Potter JE, Austin SB Tags: Ann Intern Med Source Type: research

Hypothesis: Human papillomavirus vaccination syndrome—small fiber neuropathy and dysautonomia could be its underlying pathogenesis
This article forwards the hypothesis that small fiber neuropathy and dysautonomia could be the common underlying pathogenesis to the group of rare, but severe reactions that follow HPV vaccination. Clinicians should be aware of the possible association between HPV vaccination and the development of these difficult to diagnose painful dysautonomic syndromes.
Source: Clinical Rheumatology - May 20, 2015 Category: Rheumatology Source Type: research

The human papillomavirus vaccination is not associated with risk of multiple sclerosis or other demyelinating diseases
Commentary on: Scheller NM, Svanström H, Pasternak B, et al. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA 2015;313:54–61 . Context The human papillomavirus (HPV) vaccination has been available worldwide since 2006 and over 170 million doses have been distributed. Although the HPV vaccination has demonstrated benefits in preventing precancerous lesions of the cervix, some parents forego vaccination due to safety concerns.1 While not commonly reported, concerns about neurological side effects have been aired in the media. Rigorous ...
Source: Evidence-Based Medicine - May 22, 2015 Category: Internal Medicine Authors: Perkins, R. B., Christiansen, C. L. Tags: Journalology, Epidemiologic studies, Immunology (including allergy), Vaccination / immunisation, Drugs: CNS (not psychiatric) Aetiology/Harm Source Type: research

Nuns, Warts, Viruses, and Cancer.
Authors: DiMaio D Abstract It has been known for more than 150 years that the risk of carcinoma of the uterine cervix correlates with the number of sexual partners. Laboratory and epidemiological evidence demonstrated that infection with certain human papillomavirus (HPV) types initiates the vast majority of, if not all, cervical cancer, as well as a substantial fraction of other cancers, including other anogenital cancer and oropharyngeal cancer. Pap smear testing resulted in a dramatic reduction in the incidence of cervical cancer in the developed world, and HPV vaccination has the potential to eradicate HPV-asso...
Source: The Yale Journal of Biology and Medicine - June 2, 2015 Category: Universities & Medical Training Tags: Yale J Biol Med Source Type: research